Upcoming presentation dates and time at AAN, with preliminary phase 2 timeline, page-34

This is true Groins. The SP reached highs of over $1.30, awaiting trial results. When results came back, inconclusive the SP tanked. Remember, BoD admitted mistakes were made. This time roumd they are using Biomarkers to get a more precise reading. Also, Professor Masters who was in charge of the Alzheimers trial back then, just licensed our formula exclusively for AZ. Why would Professor Masters waste his time again if he thought our drug was a flop? Just a simple question. He is raising all the cash needed to do the trial again. If he succeeds, then we are entitled to royalties, etc. Companies like people are entitled to make mistakes, as long as they corrected their wrongs, then their shouldn't be an issue. In fact, I am more comfortable with a company getting it wrong the first time than trying it out the first time. This time round, I am overly confident they have crossed all the Ts and dotted all the i's meticulously.

Stockman